3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
8
Melanoma
6
Colonic Neoplasms
4
Rectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Radiosurgery
23
Temozolomide
14
Magnetic Resonance Spectroscopy
14
pembrolizumab
11
Bevacizumab
11
Nivolumab
10
Ipilimumab
8
Specimen Handling
6
Memantine
6
abemaciclib
5
Radiotherapy
5
Mental Status and Dementia Tests
5
Blood Specimen Collection
5
Radiation
4
entrectinib
3
Surveys and Questionnaires
3
Sodium Chloride
3
Saline Solution
3
Receptors, Interleukin-8B
3
Proton Therapy
3
Lomustine
3
trastuzumab deruxtecan
2
trametinib
2
pertuzumab
2
osimertinib
2
lenvatinib
2
fluciclovine F-18
2
contrast agent BR1
2
atezolizumab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
encorafenib
×
90 days
×
Clear all
NCT04074096
2026-06-05
BEPCOME-MB
UNICANCER
Phase 2
Active not recruiting
10 enrolled